Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference
November 22, 2023 07:30 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the following investor conferences taking place November 29...
INPEFA® (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data
November 12, 2023 14:10 ET
|
Lexicon Pharmaceuticals, Inc.
Oral presentation delivered at the American Heart Association (AHA) Scientific Sessions 2023 Analysis of clinical data shows statistically significant risk reductions in heart failure and...
Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
November 10, 2023 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Healthcare Conference taking place...
Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 08, 2023 07:00 ET
|
Lexicon Pharmaceuticals, Inc.
Commercial launch of INPEFA® (sotagliflozin) as a differentiated, new treatment option for heart failure patients shows meaningful progress in Q3 with increasing demand across the cardiology community...
Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023
November 03, 2023 09:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its third quarter 2023 financial results on Wednesday, November 8th, 2023 before the...
Data on Early Clinical Benefit for INPEFA® (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023
November 02, 2023 09:00 ET
|
Lexicon Pharmaceuticals, Inc.
Cost-effectiveness data and analyses of financial impact among patients hospitalized for heart failure and treated with INPEFA included as important data selected for presentation INPEFA®...
INPEFA® (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients
November 01, 2023 09:00 ET
|
Lexicon Pharmaceuticals, Inc.
As previously reported, Express Scripts has also determined that it will list INPEFA as a preferred product on Medicare national formularies starting today, November 1, 2023 INPEFA recently approved...
Lexicon Strengthens Management Team With Two New Executives
October 31, 2023 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
Matthew Cullen Joins as Vice President of Value and Access Lisa DeFrancesco Joins as Head of Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) --...
New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting
October 30, 2023 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
Presentations from four Lexicon-sponsored studies will highlight data supporting current and potential future use of sotagliflozin INPEFA® (sotagliflozin) recently approved by FDA for treatment of...
Data From Two Studies Demonstrating Positive Financial Impact of INPEFA® (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting
October 17, 2023 16:01 ET
|
Lexicon Pharmaceuticals, Inc.
Abstracts for cost-effectiveness data and budget-impact model published in the Journal of Managed Care & Specialty Pharmacy (JMCP) INPEFA recently approved by FDA for treatment of heart failure ...